Oncology Biosimilars Market Size, Share, Growth, and Industry Analysis, By Type (G-CSF,Hematopoietic Agents,Monoclonal Antibodies), By Application (Retail pharmacies,Hospital pharmacies,Online pharmacies), Regional Insights and Forecast to 2035

Oncology Biosimilars Market Overview

The global Oncology Biosimilars Market size is projected to grow from USD 5879.63 million in 2026 to USD 6712.19 million in 2027, reaching USD 19364.28 million by 2035, expanding at a CAGR of 14.16% during the forecast period.

The global Oncology Biosimilars Market is witnessing substantial expansion, with more than 120 biosimilar oncology molecules under development and over 50 approvals worldwide as of 2024. The Oncology Biosimilars Market Research Report indicates that oncology biosimilars now account for roughly 30 % of the overall biosimilars pipeline. In 2023, oncology biosimilars captured approximately 75 % market share in the U.S. supportive-care segment, marking one of the highest uptake levels among biosimilar categories. The Oncology Biosimilars Market Outlook reveals that in 2022 the market grew by about 28 % year-on-year in unit terms and is expected to gain broad penetration across major therapeutic classes. This tremendous momentum confirms that the Oncology Biosimilars Market Size is becoming a significant segment for B2B stakeholders.In the United States the Oncology Biosimilars Market is particularly mature relative to other regions. U.S. oncology biosimilars reached average market shares of between 73 % and 87 % within the first three years after launch for major molecules. According to U.S. market analysis, the number of approved oncology biosimilars increased by over 40 % between 2021 and 2023. U.S. healthcare providers report that roughly 68 % of cancer treatment centres now have at least one oncology biosimilar in their formulary. For business-to-business players researching the Oncology Biosimilars Market Growth and Oncology Biosimilars Market Opportunities in the U.S., these figures reflect a highly dynamic environment and substantial commercial potential.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 67 % of oncology biosimilar uptake is driven by cost-saving mandates and payer policies favouring lower-cost biologic alternatives.
• Major Market Restraint: 24 % of oncologists cite lack of interchangeability and physician awareness as major barriers to oncology biosimilar prescription.
• Emerging Trends: 38 % of new oncology biosimilar entries in 2023 targeted large-molecule monoclonal antibodies originally used for breast and colorectal cancer.
• Regional Leadership: North America holds about 44 % share of global oncology biosimilar approvals as of 2024.
• Competitive Landscape: 42 % of oncology biosimilars market volume is held by the top three companies—Sandoz (~20 %), Pfizer (~15 %) and Celltrion (~12 %).
• Market Segmentation: Monoclonal antibodies (mAbs) account for more than 45 % of oncology biosimilar units in 2023.
• Recent Development: 31 % of oncology biosimilar clinical-trial initiatives in 2023 included partnership models between Indian and Western firms for global dual-market launch.

Oncology Biosimilars Market Latest Trends

The Oncology Biosimilars Market Trends reflect a transition from early filgrastim/pegfilgrastim supportive-care biosimilars toward full therapeutic oncology biosimilars like trastuzumab, rituximab and bevacizumab. In 2023, oncology biosimilars accounted for over 35 % of newly launched biosimilar products globally. Uptake rates in the U.S. show oncology biosimilars achieving shares of 73-87 % within three years of launch for key molecules. The Oncology Biosimilars Market Analysis indicates that approximately 26 new oncology biosimilar candidates entered Phase III development between 2021 and 2023, representing about 22 % increase in pipeline volume. Geographic expansion is another key trend: Asia-Pacific regions reported roughly 32 % increase in oncology biosimilar approvals between 2022 and 2023. Further, distribution channels are shifting: online pharmacies accounted for nearly 17 % of oncology biosimilar dispensing volume in 2023, up from 11 % in 2021. For B2B stakeholders examining the Oncology Biosimilars Market Forecast and Oncology Biosimilars Market Opportunities, companies that align with mAb targets, expand into emerging markets and partner with hospital-based oncology clinics are best positioned to capture growth.

Oncology Biosimilars Market Dynamics

DRIVER

"Growing global cancer incidence and the need for affordable biologic cancer therapies"

The Oncology Biosimilars Market Growth is being strongly powered by rising cancer incidence as well as pressure on healthcare systems to reduce biologic treatment costs. For example, the number of new cancer cases globally exceeded 20 million in 2022 and is expected to surpass 30 million by 2030. Oncology biosimilars provide cost-effective alternatives, leading to accelerated uptake in hospital pharmacies and oncology centres. In the U.S., oncology biosimilar uptake reached average market shares between 73 % and 87 % within three years after launch for major molecules. Biologics used in oncology accounted for more than half of biosimilar approvals by number in 2023, reinforcing their centrality. Because oncologists and payers increasingly accept biosimilars, particularly in supportive-care segments like G-CSF, adoption is extending into full therapeutic oncology domain. Such factors create sustained momentum for the Oncology Biosimilars Market Size and Oncology Biosimilars Market Share.

RESTRAINT

"Regulatory complexity, physician reluctance, and reimbursement hurdles hinder adoption"

A primary restraint for the Oncology Biosimilars Market is the combination of regulatory burden, physician hesitancy and reimbursement challenges. Approximately 24 % of oncologists in Europe and North America cite lack of interchangeability approval and low physician familiarity as key barriers to prescribing oncology biosimilars. Additionally, nearly 30 % of hospital pharmacy decision-makers report that formulary inclusion is delayed by more than 18 months post-approval due to safety and education concerns. Regulatory pathways for oncology biosimilars remain demanding because of large-molecule complexity and clinical equivalence requirements; in 2023, roughly 14 biosimilar oncology submissions required additional bridging trials, adding to time-to-market. Combined, these challenges slow the rate at which oncology biosimilars capture market share, especially in emerging economies. For B2B firms executing Oncology Biosimilars Industry Analysis, addressing physician education, payer engagement and regulatory readiness is critical to overcome adoption constraints.

OPPORTUNITY

"Emerging markets growth, biologic patent expirations, and expanding hospital/online distribution channels"

The Oncology Biosimilars Market Opportunities are expansive: by 2030 more than 70 blockbuster oncology biologics will lose exclusivity, opening biosimilar opportunities across multiple indications. Emerging markets such as China, India and Latin America are witnessing rising cancer treatment demand—Asia-Pacific approvals of oncology biosimilars increased by around 32 % between 2022 and 2023. Moreover, hospital pharmacy adoption remains high: in 2023, hospital pharmacies represented over 60 % of oncology biosimilar dispensing volume. Online pharmacy distribution gained traction, rising to approximately 17 % of dispensing volume in 2023. For B2B players targeting the Oncology Biosimilars Market Forecast, investing in emerging-market licensing, digital-distribution partnerships and key hospital networks will unlock incremental volume and value. Incorporating physician education programmes and value-based pricing strategies can further enhance market penetration and Oncology Biosimilars Market Growth potential.

CHALLENGE

"Intense competition, margin pressure and pipeline late-stage attrition in oncology biosimilars"

A significant challenge in the Oncology Biosimilars Market is the intensifying competitive landscape, margin compression and development attrition. Numerous firms are entering the oncology biosimilars sector—factories from India, Korea and Europe are targeting the same monoclonal antibody loss-of-exclusivity events. According to Corporate estimates, about 42 % of market volume is concentrated among the top three players, leaving the remainder for many smaller entrants—driving pricing pressure. Development of oncology biosimilars is complex and expensive—about 22 % of candidates in the 2021-2023 pipeline were terminated before commercialisation. Additionally, hospital procurement teams reported that more than 20 % of biosimilar oncology launches in 2023 initially achieved less than 40 % of projected volume due to formulary delays. For commercial strategy professionals reviewing the Oncology Biosimilars Market Analysis, differentiation through service offerings, regional licensing and cost-efficient manufacturing is essential to navigate these competitive challenges.

Oncology Biosimilars Market Segmentation

The Oncology Biosimilars Market Segmentation by type and application is structured as follows:

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

G-CSF: The G-CSF segment of the oncology biosimilars market (including filgrastim and pegfilgrastim biosimilars) accounted for roughly 32 % of oncology biosimilar units in 2023. These biosimilars are widely adopted in supportive oncology care; for instance, uptake in the U.S. supportive-care segment exceeded 70 % market share within three years of launch. Key B2B suppliers focus on large volumes and hospital formularies for the G-CSF type.

Hematopoietic Agents: Hematopoietic-agent biosimilars (including erythropoietin and thrombopoietin analogs) represented approximately 18 % of oncology biosimilar unit consumption in 2023. Adoption is slower compared with G-CSF due to more complex reimbursement dynamics; physician familiarity remains lower, with only about 40 % of hospital oncologists reporting routine use.

Monoclonal Antibodies (mAbs): The mAb type segment (trastuzumab, rituximab, bevacizumab biosimilars) dominated nearly 45 % of oncology biosimilar value share in 2023. More than 26 new mAb oncology biosimilars entered late-stage development by end-2023, representing about 38 % of the entire oncology biosimilar pipeline. This type is the key focal area for B2B suppliers and manufacturers.

BY APPLICATION

Retail Pharmacies: Oncology biosimilars dispensed via retail pharmacies accounted for approximately 22 % of total units in 2023, and are projected to expand as outpatient oncology care increases. Retail chains and mail-order models are increasingly included in formulary strategies, with about 14 % of oncology biosimilar prescriptions in 2023 fulfilled through online-retail channels.

Hospital Pharmacies: Hospital pharmacies remain the largest application channel, representing around 60 % of oncology biosimilar dispensing volume in 2023. For B2B stakeholders, hospital systems provide the primary distribution and formulary environment; more than 110 major cancer centres in North America and Europe added oncology biosimilar formularies in 2023.

Online Pharmacies: Online pharmacy or digital-dispensing channels held about 18 % share of oncology biosimilar volumes in 2023, up from 11 % in 2021. The Oncology Biosimilars Market Trends highlight that online fulfilment models are gaining traction as outpatient oncology treatment moves to home-based care settings and patient convenience becomes a differentiator.

Oncology Biosimilars Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

In North America the Oncology Biosimilars Market holds the dominant position globally, with approximately 44 % of worldwide approvals and estimated share of total oncology biosimilar consumption in 2023. The United States leads with average market shares for oncology biosimilars ranging from 73 % to 87 % within the first three years of launch for major molecules. Canada contributes a smaller portion, with approximately 12 % of North American oncology biosimilar uptake in 2023. The North American oncology biosimilars ecosystem is supported by over 50 biologic-reference products that have lost exclusivity between 2021-2024, creating substantial B2B opportunity. Furthermore, approximately 165 hospital-based oncology centres in the U.S. implemented biosimilar protocols for mAbs in 2023. For B2B market entrants analysing the Oncology Biosimilars Market Forecast, North America remains the most mature, highest-volume, and highest-penetration region, although competition and pricing pressure are intense.

The North America Oncology Biosimilars Market is estimated at around USD 2,326.1 million in 2025, representing roughly 45.2% of the global market. The region benefits from high biosimilar uptake where oncology-biosimilar market shares for key molecules reached between 73% and 87% in their first three years post-launch. For B2B stakeholders studying the Oncology Biosimilars Market Forecast, North America remains the highest-value region with deep hospital and oncology infrastructure, strong payer reimbursement, and mature manufacturing and distribution networks.

North America – Major Dominant Countries in the Oncology Biosimilars Market

• United States: The U.S. market size is estimated at approximately USD 2,100.0 million in 2025, capturing about 90.3% of the North America region.
• Canada: Canada’s market size is estimated at USD 145.0 million in 2025, representing about 6.2% of the region.
• Mexico: Mexico’s market size is estimated at USD 55.0 million in 2025, accounting for around 2.4% of North America.
• Puerto Rico: The market size is estimated at USD 18.0 million in 2025, representing about 0.8% of the region.
• Greenland/territories: Estimated at USD 8.0 million in 2025, representing about 0.3% of the region.

Europe

Europe’s Oncology Biosimilars Market accounts for roughly 30 % of global consumption and has established biosimilar infrastructure across the U.K., Germany, France, Italy and Spain. As of 2023, about 85 % of European oncology treatment centres included at least one biosimilar mAb in their formulary. The region benefits from regulatory harmonisation under the EMA, which fast-tracked over 20 oncology biosimilar approvals between 2020-2023. Italy and Spain reported more than 60 % uptake rates for trastuzumab biosimilars within two years of launch in 2022. For business-to-business stakeholders compiling the Oncology Biosimilars Industry Report, Europe offers stable demand, high awareness, strong payer frameworks and significant scale potential, though market growth is more moderate compared to emerging regions.

The Europe Oncology Biosimilars Market is estimated at about USD 1,545.1 million in 2025, representing the second-largest regional share at roughly 30.0% of global volume. Europe’s regulatory environment and high biosimilar penetration (for example mAb biosimilars) give the region strong foundations for the Oncology Biosimilars Market Growth.

Europe – Major Dominant Countries in the Oncology Biosimilars Market

• Germany: Germany’s market size is estimated at USD 460.0 million in 2025, accounting for about 29.8% of Europe.
• United Kingdom: The UK’s market size is estimated at USD 390.0 million in 2025, representing around 25.3% of Europe.
• France: France’s market size is estimated at USD 220.0 million in 2025, capturing approximately 14.3% of Europe.
• Italy: Italy’s market size is estimated at USD 180.0 million in 2025, representing roughly 11.7% of the region.
• Spain: Spain’s market size is estimated at USD 140.0 million in 2025, equating to around 9.1% of Europe.

Asia-Pacific

The Asia-Pacific region is emerging strongly in the Oncology Biosimilars Market, contributing approximately 20 % of global uptake in 2023, with notable growth in China, India, Japan, South Korea and Australia. China alone saw more than 32 % increase in oncology biosimilar approvals between 2022 and 2023, while India recorded over 12 new oncology biosimilar launches in 2023. Japan’s oncology biosimilar uptake increased by around 22 % in 2023 compared to 2022. The large untreated cancer patient pool, rising healthcare expenditure, and growing biosimilar manufacturing capacity underpin the region’s significance for B2B investors. For those studying the Oncology Biosimilars Market Growth, Asia-Pacific represents high-growth opportunity, though regulatory fragmentation and price-sensitivity remain relevant considerations.

The Asia-Pacific Oncology Biosimilars Market is estimated at approximately USD 1,028.8 million in 2025, representing around 20.0% of the global market. The region is gaining traction rapidly with rising cancer incidence, increasing biosimilar manufacturing and improving healthcare access—creating major opportunities for business-to-business participants.

Asia – Major Dominant Countries in the Oncology Biosimilars Market

• China: China’s market size is estimated at USD 310.0 million in 2025, representing about 30.1% of the Asia region.
• Japan: Japan’s market size is estimated at USD 250.0 million in 2025, capturing approximately 24.3% of Asia-Pacific.
• India: India’s market size is estimated at USD 150.0 million in 2025, equating to about 14.6% of the region.
• South Korea: South Korea’s market size is estimated at USD 140.0 million in 2025, representing roughly 13.6% of Asia.
• Australia: Australia’s market size is estimated at USD 78.8 million in 2025, accounting for around 7.7% of the region.

Middle East & Africa

In Middle East & Africa the Oncology Biosimilars Market remains nascent, accounting for roughly 6 % of global consumption in 2023, yet displays strong growth potential driven by government programmes and healthcare infrastructure expansion. For example, Gulf Cooperation Council (GCC) countries implemented biosimilar adoption policies in cancer treatment centres increasing biosimilar share by approximately 14 % in 2023. Countries such as Saudi Arabia and UAE reported formulary inclusion of oncology biosimilars in over 20 major hospitals in 2023. Although volume remains smaller compared to other regions, for B2B firms examining the Oncology Biosimilars Market Insights, this region offers green-field opportunities in market access, local manufacturing partnerships and payer-driven cost containment.

The Middle East & Africa Oncology Biosimilars Market is estimated at approximately USD 250.4 million in 2025, representing about 4.9% of global market size. For B2B entities analysing the Oncology Biosimilars Market Insights, this region offers emerging potential with increasing healthcare investment and biosimilar initiatives, though absolute volume remains smaller compared to established regions.

Middle East & Africa – Major Dominant Countries in the Oncology Biosimilars Market

• Saudi Arabia: Saudi Arabia’s market size is estimated at USD 80.0 million in 2025, representing about 32.0% of the Middle East & Africa region.
• United Arab Emirates: UAE’s market size is estimated at USD 65.0 million in 2025, accounting for approximately 26.0% of that region.
• South Africa: South Africa’s market size is estimated at USD 45.0 million in 2025, capturing roughly 18.0% of the region.
• Nigeria: Nigeria’s market size is estimated at USD 35.0 million in 2025, representing about 14.0% of the region.
• Kenya: Kenya’s market size is estimated at USD 25.4 million in 2025, accounting for around 10.2% of the regional segment.

List of Top Oncology Biosimilars Companies

• Reddy’s Laboratories
• Mylan
• Biocon
• Pfizer Inc.
• Sandoz International GmbH
• Apotex Inc.
• Intas Pharmaceuticals Ltd.
• F Hoffmann-La Roche
• STADA Arzneimittel AG
• Teva Pharmaceutical Industries Ltd.
• Celltrion Inc.
• BIOCAD

Top Two Companies With Highest Share

• Sandoz International GmbH – holds a leading share in the oncology biosimilars market, estimated at approximately 18-22 % globally, with broad portfolios across key oncology biosimilar molecules.
• Pfizer Inc. – commands a significant share of around 14-18 % of the oncology biosimilars market globally, leveraging its strong regulatory and manufacturing presence across regions.

Investment Analysis and Opportunities

Investment analysis in the Oncology Biosimilars Market reveals growing capital deployment into manufacturing, partnership alliances and geographic expansion strategies. In 2023, more than 35 licensing deals were signed globally for oncology biosimilar development and commercialization, representing roughly 28 % increase compared to 2022. Emerging markets such as Asia-Pacific account for about 20 % of global uptake but represent over 40 % of new investment activity in 2023. For business-to-business investors researching the Oncology Biosimilars Market Opportunities, key avenues include manufacturing scale-up to exploit upcoming biologic patent expirations, hospital formulary access growth (which comprises roughly 60 % of dispensing volume), and online pharmacy expansion (which rose to about 17 % of unit volume in 2023). In addition, co-development partnerships between Indian manufacturers and Western firms increased by roughly 22 % in 2023, indicating a strong pipeline collaboration trend. Investment drivers also include policy shifts in the U.S. and Europe favouring biosimilar reimbursement and uptake, where oncology biosimilars achieved market shares of 73-87 % in early years post-launch. For companies and investors leveraging the Oncology Biosimilars Market Forecast, building integrated manufacturing, regulatory and distribution strategies will be key to capturing early mover advantage and volume growth.

New Product Development

Innovation in the Oncology Biosimilars Market is accelerating, with approximately 26 late-stage monoclonal antibody biosimilars under development by end of 2023, representing around 38 % of the oncology biosimilar pipeline. In 2023, more than 12 oncology biosimilar candidates targeting trastuzumab/rituximab analogues entered Phase III trials, reflecting a ~22 % increase in pipeline volume over the prior year. Product developers are also advancing formulations tailored for hospital outpatient infusion settings and exploring subcutaneous delivery options, with about 15 % of new entries in 2023 featuring subcutaneous formats. Furthermore, digital health integration is becoming an enabler: approximately 8 % of oncology biosimilar launches in 2023 included patient-support programmes via online channels. For B2B suppliers reviewing the Oncology Biosimilars Market Trends, strategic focus on high-value mAb biosimilars, secure supply-chain scale-up, and partnerships with oncology centres will be critical for winning product development cycles and market share.

Five Recent Developments

• In 2023, a leading Indian manufacturer signed a global co-marketing agreement for an oncology biosimilar of bevacizumab, representing a deal covering over 40 countries and expansion into emerging markets.
• In 2022, the U.S. regulatory agency approved an oncology biosimilar for trastuzumab, marking one of the first approvals of a therapeutic oncology biosimilar beyond supportive-care agents.
• In 2023, hospital formulary adoption increased, with more than 110 major oncology centres in North America adding at least one biosimilar mAb to their cancer-treatment portfolios.
• In 2023, online pharmacy dispensing of oncology biosimilars grew to approximately 17 % of total unit volume, up from about 11 % in 2021, reflecting digital distribution trends.
• In 2023, three major biopharma companies announced joint manufacturing capacity expansions for oncology biosimilars, collectively adding an estimated 120 MLN units of annual capacity across Europe and Asia-Pacific.

Report Coverage of Oncology Biosimilars Market

The Oncology Biosimilars Market Report provides extensive coverage across various dimensions: product-type segmentation (G-CSF, hematopoietic agents and monoclonal antibodies), distribution-channel segmentation (retail pharmacies, hospital pharmacies and online pharmacies) and geographic segmentation (North America, Europe, Asia-Pacific, Middle East & Africa). The scope includes quantitative data such as monoclonal antibodies accounting for approximately 45 % of oncology biosimilar value share in 2023, and hospital pharmacies representing around 60 % of dispensing volume that year. Competitive profiling is rigorous: top players like Sandoz and Pfizer hold about 18-22 % and 14-18 % global share respectively. Trend analysis highlights that 38 % of new oncology biosimilar entrants in 2023 target therapeutic mAbs, and online pharmacy share climbed from 11 % in 2021 to 17 % in 2023. With this comprehensive approach, the report offers B2B stakeholders actionable insights into Oncology Biosimilars Market Size, Oncology Biosimilars Market Share, Oncology Biosimilars Market Growth and Oncology Biosimilars Market Opportunities.

Oncology Biosimilars Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 5879.63 Million in 2026
Market Size Value By	USD 19364.28 Million by 2035
Growth Rate	CAGR of 14.16% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : G-CSF Hematopoietic Agents Monoclonal Antibodies By Application : Retail pharmacies Hospital pharmacies Online pharmacies
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample